Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has earned an average rating of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $38.50.

CNTA has been the topic of a number of recent research reports. Oppenheimer lifted their target price on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Chardan Capital reissued a “buy” rating and set a $30.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. Guggenheim upped their target price on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Finally, B. Riley boosted their price target on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, December 1st.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $24.57 on Friday. The stock’s 50-day moving average is $25.56 and its two-hundred day moving average is $22.42. The firm has a market cap of $3.30 billion, a price-to-earnings ratio of -13.43 and a beta of 1.56. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $30.58.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). Analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Mario Alberto Accardi sold 10,000 shares of the firm’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the sale, the insider owned 178,801 shares in the company, valued at approximately $5,364,030. This trade represents a 5.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO Tia L. Bush sold 40,000 shares of Centessa Pharmaceuticals stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the completion of the sale, the chief technology officer directly owned 121,503 shares in the company, valued at approximately $3,159,078. The trade was a 24.77% decrease in their position. The SEC filing for this sale provides additional information. 7.09% of the stock is currently owned by corporate insiders.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors have recently modified their holdings of CNTA. TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals in the fourth quarter worth $25,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Centessa Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after buying an additional 979 shares in the last quarter. DNB Asset Management AS acquired a new position in Centessa Pharmaceuticals during the third quarter worth about $218,000. Sigma Planning Corp purchased a new position in Centessa Pharmaceuticals in the fourth quarter valued at about $225,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter valued at approximately $218,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.